Breaking Down Miracll Chemicals Co.,Ltd Financial Health: Key Insights for Investors

Curious whether Miracll Chemicals (300848.SZ) is a specialty-chemical sleeper or a stretched bet? Consider the hard facts: revenue edged to CNY 412.90M in Q2 (June 30, 2025) with a TTM revenue of CNY 1.66B (+6.55% YoY and +12.42% vs. 2023), revenue per employee ~CNY 2.55M across 651 staff, and a market cap of CNY 6.93B (share price CNY 15.90 on Oct 13, 2025); profitability shows TTM net income of CNY 85.30M (net margin 5.02%, ROE 4.54%, EPS CNY 0.21, trailing P/E 70.60, forward P/E 31.68), while capital structure reveals total debt CNY 1.55B vs. cash CNY 823.43M (net debt -CNY 724.40M), debt/equity 0.88, interest coverage 3.84, current ratio 1.23 and quick ratio 0.80-yet valuation metrics (P/S 4.18, P/B 3.63, EV/Revenue 4.30, EV/EBITDA 59.27) and risk scores (Altman Z 2.33, Piotroski F‑Score 6) raise flags; juxtaposed with strategic bets on TPU for 3D printing, EV and sustainable-materials markets and continued capacity and R&D investment, these numbers set the stage for a deeper dive into where value and risk intersect for investors.

Miracll Chemicals Co.,Ltd (300848.SZ) - Revenue Analysis

Key topline figures for Miracll Chemicals Co.,Ltd (300848.SZ) illustrate recent stability in quarterly receipts alongside multi-period growth metrics that investors should weigh against valuation multiples and operational productivity.

• Quarter ending 30 June 2025: revenue CNY 412.90 million (QoQ change: -0.43%).
• Trailing twelve months (TTM) revenue: CNY 1.66 billion (YoY growth: +6.55%).
• Full-year 2024 revenue: CNY 1.66 billion (2024 vs 2023: +12.42%).
• Revenue per employee: ~CNY 2.55 million (total employees: 651).
• Price-to-Sales (P/S) ratio: 4.18.
• Market capitalization: CNY 6.93 billion; stock price: CNY 15.90 (as of 13 Oct 2025).

For background reading on corporate history, ownership and business model, see: Miracll Chemicals Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

Miracll Chemicals Co.,Ltd (300848.SZ) - Profitability Metrics

• Net income (TTM): CNY 85.30 million - net profit margin 5.02%
• Return on equity (ROE): 4.54%
• Earnings per share (EPS): CNY 0.21 - trailing P/E: 70.60
• Operating margin: 4.38%
• EBITDA margin: 7.23%
• Gross margin: 13.28%

Miracll Chemicals Co.,Ltd (300848.SZ) - Debt vs. Equity Structure

• Debt-to-equity ratio: 0.88 - a balanced leverage level indicating debt is material but not dominant.
• Total debt: CNY 1,550,000,000.
• Cash & cash equivalents: CNY 823,430,000, resulting in a reported net cash position of -CNY 724,400,000 (net debt).
• Interest coverage ratio (EBIT / interest expense): 3.84 - operating income covers interest ~3.8x.
• Quick ratio: 0.80 - limited immediate liquidity when inventories are excluded.
• Current ratio: 1.23 - adequate short-term coverage of current liabilities by current assets.
• Enterprise value / EBITDA: 59.27 - a high multiple signaling market valuation relative to EBITDA.

• Balance-of-risk: Debt-to-equity ~0.88 suggests financing risk is material but not excessive; net debt near CNY 0.72-0.73 billion increases sensitivity to earnings volatility.
• Liquidity profile: Current ratio 1.23 vs. quick ratio 0.80 highlights dependence on inventory or receivables conversion to meet short-term needs.
• Coverage and cost: Interest coverage 3.84 affords coverage but limited margin if operating income declines; refinancing or rising rates could pressure interest expense coverage.
• Valuation lens: EV/EBITDA 59.27 signals the market attributes strong growth expectations or limited current EBITDA relative to enterprise value; this elevates valuation risk if earnings disappoint.

Miracll Chemicals Co.,Ltd (300848.SZ) - Liquidity and Solvency

• Current ratio: 1.23 - covers short-term liabilities, but margin of safety is limited.
• Quick ratio: 0.80 - indicates reliance on inventory to meet near-term obligations.
• Interest coverage ratio: 3.84 - operating income covers interest ~3.8x, providing a cushion but not a wide margin.
• Debt-to-equity ratio: 0.88 - moderate leverage, below 1.0 but materially funded by debt.
• Net cash position: -CNY 724.40 million - net debtor position, increasing refinancing or liquidity risk.
• EV/EBITDA: 59.27 - very high valuation relative to EBITDA, implying expectations of strong future earnings or thin current EBITDA.

• Strengths: Positive current ratio and interest coverage indicate operational ability to meet obligations under normal conditions.
• Risks: Net debt of CNY 724.40M plus a quick ratio below 1 and EV/EBITDA of 59.27 heighten sensitivity to cash-flow shocks or earnings disappointments.
• Key watch items for investors: inventory turnover trends, near-term debt maturities and refinancing terms, trajectory of EBITDA growth to justify the current EV/EBITDA.

Miracll Chemicals Co.,Ltd (300848.SZ) - Valuation Analysis

• Trailing P/E: 70.60 - the market is paying 70.6x last 12 months' earnings, reflecting high historical earnings multiple.
• Forward P/E: 31.68 - expected earnings improvement discounts current price to ~31.7x next-12-months EPS.
• P/S: 4.18 - investors pay about 4.18x annual sales, indicating revenue multiple is elevated versus commodity chemical peers.
• P/B: 3.63 - the stock trades at 3.63x book value, implying a premium to net asset base.
• EV/Revenue: 4.30 - enterprise value equals 4.30x sales, useful for capital structure-neutral comparisons.
• EV/EBITDA: 59.27 - very high, showing the company's enterprise value is ~59.3x EBITDA, signaling stretched valuation relative to cash-operating-profit.

• Expectation gap: The drop from trailing P/E (70.60) to forward P/E (31.68) implies the market anticipates material EPS improvement; verify guidance and analyst drivers behind that expectation.
• Revenue vs. profit tension: P/S (4.18) and EV/Revenue (4.30) show revenue is being valued richly, but EV/EBITDA (59.27) warns profitability (or reported EBITDA) is not yet commensurate with that revenue multiple.
• Balance-sheet premium: P/B of 3.63 suggests investors accept paying well above net asset value-assess intangible assets, margins, and ROE to justify this premium.
• Risk sensitivity: High multiples amplify downside risk if growth disappoints; stress-test valuation with slower revenue or margin scenarios.

Miracll Chemicals Co.,Ltd (300848.SZ) Risk Factors

• Altman Z-Score: 2.33 - moderate bankruptcy risk territory; not safe but not in imminent distress.
• Piotroski F-Score: 6 - indicates reasonable accounting quality and operational improvement, but not best-in-class.
• Debt-to-Equity Ratio: 0.88 - a moderate leverage level that implies material reliance on debt financing.
• Quick Ratio: 0.80 - below 1.0, signaling potential short-term liquidity pressure to meet immediate obligations.
• Net Cash Position: -CNY 724.40 million - net debt position, meaning liabilities exceed cash holdings.
• EV/EBITDA: 59.27 - very high valuation multiple relative to operating earnings, raising concerns about price vs. fundamentals.

• Liquidity pressure (quick ratio 0.80) combined with net debt (-CNY 724.40m) increases sensitivity to revenue shocks or rising interest costs.
• Leverage at 0.88 is manageable in stable conditions but reduces flexibility during downturns; refinancing risk exists if credit markets tighten.
• Altman Z-Score of 2.33 warrants monitoring: a deterioration in profitability or asset quality could push the score into distress levels.
• EV/EBITDA of 59.27 suggests market expectations of strong future growth - if growth disappoints, valuation re-rating risk is high.
• Piotroski F-Score of 6 supports that the company has some positive internal signals (profitability, cash flow, and balance sheet changes), but not enough to offset liquidity and valuation concerns.

Miracll Chemicals Co.,Ltd (300848.SZ) - Growth Opportunities

• Focus on customized TPU solutions for specialized applications (medical-grade, high-performance elastomers, filament for 3D printing) to command premiums versus commodity TPU.
• Targeting high-growth end-markets - 3D printing, sustainable materials, electric vehicles (EVs), and renewable energy - where technical performance and material innovation justify price premiums and longer product lifecycles.
• Capital allocation toward capacity expansion, pilot lines for specialty grades, and technological upgrades to shorten time-to-market and protect margins as volumes scale.
• Leveraging integrated R&D and manufacturing to move up the value chain and differentiate from commodity chemical producers through formulation IP and process know-how.
• Prioritizing product innovation and application development to navigate competitive pressures and capture adjacent market share in engineering plastics and advanced elastomers.

• 3D printing filaments and elastomeric resins: customized shore hardness and flow properties to target prototyping and industrial printing markets where margins are higher than commodity filament.
• Sustainable materials: bio-based polyols, recyclable TPU formulations, and additives that enhance lifecycle performance-addressing circularity requirements from large OEMs.
• EV & renewable energy applications: vibration-damping components, cable sheathing, and encapsulants where thermal, chemical, and mechanical performance are critical.
• Value-added services: co-development, application testing, and certification pathways to accelerate customer adoption and embed Miracll into design wins.

• Achievement of >40% revenue from specialty/premium TPU products by 2026.
• Successful commissioning of new specialty TPU lines (target capacity add: 25-30k tpa) by end-2025.
• Increase R&D intensity to ~6% of revenue and publish customer qualification dossiers for EV/renewables applications by 2025.
• New design wins in 3D printing and at least two OEM engagements in EV component supply chains within 24 months.